1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of Immunotherapy
3.3. History of Cancer Immunotherapy
3.4. Limitations of Cancer Immunotherapy
3.5. Targeting Tumor-Specific Neoantigens
3.5.1. Types of Neoantigens
3.5.2. Role of Neoantigens in Cancer Immunotherapy
3.5.3. Neoantigen Targeted Therapies
3.5.3.1. Identification and Selection of Neoantigens
3.5.3.2. Delivery of Neoantigen Targeted Therapies
3.6. Key Challenges and Future Perspectives
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Neoantigen Targeted Therapies: Marketed and Development Pipeline
4.3. Neoantigen Targeted Therapies: Pipeline Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Type of Molecule
4.3.3. Analysis by Type of Immunotherapy
4.3.4. Analysis by Type of Therapy
4.3.5. Analysis by Route of Administration
4.3.6. Analysis by Target Disease Indication
4.3.7. Analysis by Type of Neoantigen
4.3.8. Analysis by Line of Therapy
4.3.9. Funnel Analysis: Analysis by Phase of Development, Type of Immunotherapy and Type of Therapy
4.3.10. Heptagon Representation: Analysis by Phase of Development and Route of Administration
4.4. Neoantigen Targeted Therapies: List of Drug Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size and Geographical Location
4.4.3. Leading Developers
4.4.4. Analysis by Geography
4.5. Grid Analysis: Analysis by Target Disease Indication, Company Size and Location
5. COMPANY PROFILES: NEOANTIGEN TARGETED THERAPIES
5.1. Chapter Overview
5.2. Bavarian Nordic
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Neoantigen Targeted Therapies Portfolio
5.2.4. Recent Collaborations
5.2.5. Future Outlook
5.3. Genocea Biosciences
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Neoantigen Targeted Therapies Portfolio
5.3.4. Recent Collaborations
5.3.5. Future Outlook
5.4. Gradalis
5.4.1. Company Overview
5.4.2. Neoantigen Targeted Therapies Portfolio
5.4.3. Recent Collaborations
5.4.4. Future Outlook
5.5. Immunicum
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Neoantigen Targeted Therapies Portfolio
5.5.4. Recent Collaborations
5.5.5. Future Outlook
5.6. Immunovative Therapies
5.6.1. Company Overview
5.6.2. Neoantigen Targeted Therapies Portfolio
5.6.3. Recent Collaborations
5.6.4. Future Outlook
5.7. Iovance Biotherapeutics
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Neoantigen Targeted Therapies Portfolio
5.7.4. Recent Collaborations
5.7.5. Future Outlook
5.8. MediGene
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Neoantigen Targeted Therapies Portfolio
5.8.4. Recent Collaborations
5.8.5. Future Outlook
5.9. Neon Therapeutics
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Neoantigen Targeted Therapies Portfolio
5.9.4. Recent Collaborations
5.9.5. Future Outlook
6. PUBLICATION ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Neoantigen Targeted Therapies: List of Publications
6.3.1. Analysis by Year of Publication
6.3.2. Analysis by Type of Study
6.3.3. Analysis by Study Objective
6.3.4. Analysis by Affiliated Therapies
6.3.5. Analysis by Target Disease Indication
6.3.6. Key Journals: Analysis by Number of Publications
7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Neoantigen Targeted Therapies: Patent Analysis
7.3.1. Analysis by Publication Year
7.3.2. Analysis by Geographical Location
7.3.3. Analysis by CPC Classifications
7.3.4. Analysis by Type of Industry
7.3.5. Emerging Focus Areas
7.3.6. Leading Players: Analysis by Number of Patents
7.4. Neoantigen Targeted Therapies: Patent Benchmarking Analysis
7.4.1. Analysis by Patent Characteristics
7.5. Neoantigen Targeted Therapies: Patent Valuation Analysis
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Neoantigen Targeted Therapies: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Immunotherapy
8.3.4. Analysis by Type of Partnership and Type of Product
8.3.5. Analysis by Type of Partnership and Target Disease Indication
8.3.6. Regional Analysis
8.3.7. Most Active Players: Analysis by Number of Partnerships
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Neoantigen Targeted Therapies: Funding and Investment Analysis
9.3.1. Analysis by Number of Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Amount Invested across Different Types of Therapies
9.3.5. Analysis by Amount Invested across Different Types of Indications
9.3.4. Analysis by Geography
9.3.5. Most Active Players: Analysis by Amount of Funding
9.3.6. Most Active Investors: Analysis by Number of Instances
9.4. Concluding Remarks
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1 Chapter Overview
10.2. Key Assumptions and Forecast Methodology
10.3. Global Neoantigen Targeted Therapies Market, 2019-2030
10.3.1. Global Neoantigen Targeted Therapies Market: Distribution by Region, 2019-2030 (USD Million)
10.3.2. Global Neoantigen Targeted Therapies Market: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.3.2.1. Global Neoantigen Targeted Therapies Market for Bone and Cartilage Cancer, 2019-2030 (USD Million)
10.3.2.2. Global Neoantigen Targeted Therapies Market for Colorectal Cancer, 2019-2030
10.3.2.3. Global Neoantigen Targeted Therapies Market for Gynecological Cancers, 2019-2030 (USD Million)
10.3.2.4. Global Neoantigen Targeted Therapies Market for Head and Neck Cancer, 2019-2030 (USD Million)
10.3.2.5. Global Neoantigen Targeted Therapies Market for Hepatocellular Carcinoma, 2019-2030 (USD Million)
10.3.2.6. Global Neoantigen Targeted Therapies Market for Lung Cancer, 2019-2030 (USD Million)
10.3.2.7. Global Neoantigen Targeted Therapies Market for Renal Carcinoma, 2019-2030 (USD Million)
10.3.2.8. Global Neoantigen Targeted Therapies Market for Other Cancers, 2019-2030 (USD Million)
10.3.3. Global Neoantigen Targeted Therapies Market: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.3.3.1. Global Neoantigen Targeted Therapies Market for Personalized Neoantigen Targeted Therapies, 2019-2030 (USD Million)
10.3.3.2. Global Neoantigen Targeted Therapies Market for Off-the-shelf Neoantigen Targeted Therapies, 2019-2030 (USD Million)
10.3.4. Global Neoantigen Targeted Therapies Market: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.3.4.1. Global Neoantigen Targeted Therapies Market for Dendritic Cell Vaccines, 2019-2030 (USD Million)
10.3.4.2. Global Neoantigen Targeted Therapies Market for DNA / RNA-based Vaccines, 2019-2030 (USD Million)
10.3.4.3. Global Neoantigen Targeted Therapies Market for Protein / Peptide-based Vaccines, 2019-2030 (USD Million)
10.3.4.4. Global Neoantigen Targeted Therapies Market for TIL-based Therapies, 2019-2030 (USD Million)
10.3.5. Global Neoantigen Targeted Therapies Market: Distribution by Route of Administration, 2019-2030 (USD Million)
10.3.5.1. Global Neoantigen Targeted Therapies Market for Intradermal Route of Administration, 2019-2030 (USD Million)
10.3.5.2. Global Neoantigen Targeted Therapies Market for Intravenous Route of Administration, 2019-2030 (USD Million)
10.3.5.3. Global Neoantigen Targeted Therapies Market for Subcutaneous Route of Administration, 2019-2030 (USD Million)
10.3.5.4. Global Neoantigen Targeted Therapies Market for Other Routes of Administration, 2019-2030 (USD Million)
10.4. Neoantigen Targeted Therapies Market in the US, 2019-2030 (USD Million)
10.4.1. Neoantigen Targeted Therapies Market in the US: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.4.2. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.4.3. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.4.3. Neoantigen Targeted Therapies Market in the US: Distribution by Route of Administration, 2019-2030 (USD Million)
10.5. Neoantigen Targeted Therapies Market in the UK, 2019-2030 (USD Million)
10.5.1. Neoantigen Targeted Therapies Market in the UK: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.5.2. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.5.3. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.5.4. Neoantigen Targeted Therapies Market in the UK: Distribution by Route of Administration, 2019-2030 (USD Million)
10.6. Neoantigen Targeted Therapies Market in Germany, 2019-2030 (USD Million)
10.6.1. Neoantigen Targeted Therapies Market in Germany: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.6.2. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.6.3. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.6.4. Neoantigen Targeted Therapies Market in Germany: Distribution by Route of Administration, 2019-2030 (USD Million)
10.7. Neoantigen Targeted Therapies Market in France, 2019-2030 (USD Million)
10.7.1. Neoantigen Targeted Therapies Market in France: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.7.2. Neoantigen Targeted Therapies Market in France: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.7.3. Neoantigen Targeted Therapies Market in France: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.7.4. Neoantigen Targeted Therapies Market in France: Distribution by Route of Administration, 2019-2030 (USD Million)
10.8. Neoantigen Targeted Therapies Market in Italy, 2019-2030 (USD Million)
10.8.1. Neoantigen Targeted Therapies Market in Italy: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.8.2. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.8.3. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.8.4. Neoantigen Targeted Therapies Market in Italy: Distribution by Route of Administration, 2019-2030 (USD Million)
10.9. Neoantigen Targeted Therapies Market in Spain, 2019-2030 (USD Million)
10.9.1. Neoantigen Targeted Therapies Market in Spain: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.9.2. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.9.3. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.9.4. Neoantigen Targeted Therapies Market in Spain: Distribution by Route of Administration, 2019-2030 (USD Million)
10.10. Neoantigen Targeted Therapies Market in Rest of the World, 2019-2030 (USD Million)
10.10.1. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Target Disease Indication, 2019-2030 (USD Million)
10.10.2. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
10.10.3. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
10.10.4. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (USD Million)
11. CONCLUDING REMARKS12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. AIVITA Biomedical
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Gabriel Nistor (Chief Scientific Officer)
12.3. BioLineRx
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Ella Sorani (Vice President Research and Development)
12.3. VAXIMM
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Heinz Lubenau (Chief Operating Officer and Co-Founder)
13. APPENDIX 1: TABULATED DATA14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONSList of Figures
Figure 3.1. Global Age-Standardized Incidence Rates of Cancer in 2018 (per 100,000
Figure 3.2. Four Pillars of Cancer Therapy
Figure 3.3. Evolution of Cancer Immunotherapy
Figure 3.4. Limitations of Cancer Immunotherapy
Figure 3.5. Personalized and Off-the-shelf Neoantigens
Figure 3.6. Next Generation Sequencing of Neoantigens: Process Steps
Figure 4.1. Neoantigen Targeted Therapies: Distribution by Phase of Development
Figure 4.2. Neoantigen Targeted Therapies: Distribution by Type of Molecule
Figure 4.3. Neoantigen Targeted Therapies: Distribution by Type of Immunotherapy
Figure 4.4. Neoantigen Targeted Therapies: Distribution by Type of Therapy
Figure 4.5. Neoantigen Targeted Therapies: Distribution by Route of Administration
Figure 4.6. Neoantigen Targeted Therapies: Distribution by Target Disease Indication
Figure 4.7. Neoantigen Targeted Therapies: Distribution by Type of Neoantigen
Figure 4.8. Neoantigen Targeted Therapies: Distribution by Line of Therapy
Figure 4.9. Funnel Analysis: Distribution by Phase of Development, Type of Immunotherapy and Type of Therapy
Figure 4.10. Heptagon Representation: Distribution by Phase of Development and Route of Administration
Figure 4.11. Neoantigen Targeted Therapy: Distribution by Year of Establishment of Developer
Figure 4.12. Neoantigen Targeted Therapies: Distribution by Company Size and Geographical Location
Figure 4.13. Leading Developers: Distribution by Number of Therapies
Figure 4.14. Neoantigen Targeted Therapies: Distribution by Geographical Location of Developer
Figure 4.15. Grid Analysis: Distribution by Target Disease Indication, Company Size and Location
Figure 5.1. Bavarian Nordic: Annual Revenues, FY2014-FY2018 (DKK Million)
Figure 5.2. Medigene: Annual Revenues, FY2014-FY2018 (EUR Million)
Figure 6.1. Publications: Distribution by Year of Publication
Figure 6.2. Publications: Distribution by Type of Study
Figure 6.3. Publications: Distribution by Study Objective
Figure 6.4. Publications: Distribution by Affiliated Therapies
Figure 6.5. Publications: Distribution by Target Disease Indication
Figure 6.6. Key Journals: Distribution by Number of Publications
Figure 7.1. Patent Analysis: Distribution by Type of Patent
Figure 7.2. Patent Analysis: Cumulative Distribution by Publication Year, Pre2010-2019
Figure 7.3. Patent Analysis: Distribution by Geographical Location
Figure 7.4. Patent Analysis: Distribution by Geographical Location, 2000-2009 and 2010-2019
Figure 7.5. Patent Analysis: Distribution by CPC Classification Symbols
Figure 7.6. Patent Analysis: Emerging Focus Areas
Figure 7.7. Patent Analysis: Distribution by Type of Applicant
Figure 7.8. Leading Industry Players: Distribution by Number of Patents
Figure 7.9. Leading Non-Industry Players: Distribution by Number of Patents
Figure 7.10. Leading Individual Assignees: Distribution by Number of Patents
Figure 7.11. Patent Analysis: Benchmarking by Patent Characteristics
Figure 7.12. Patent Analysis: Distribution by Patent Age (January 2000 - April 2019)
Figure 7.13. Patent Analysis: Valuation Analysis
Figure 8.1. Partnerships and Collaborations: Cumulative Trend by Year, 2014-2019
Figure 8.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3. Partnerships and Collaborations: Distribution by Type of Partnership, 2014-2016 and 2017-2019
Figure 8.4. Partnerships and Collaborations: Distribution by Type of Product
Figure 8.5. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Immunotherapy
Figure 8.6. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Target Disease Indication
Figure 8.7. Most Active Players: Distribution by Number of Partnerships
Figure 8.8. Partnership and Collaborations: Regional Distribution
Figure 8.9. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 9.1. Distribution by Type of Funding and Year of Establishment of Company, 2014-2019
Figure 9.2. Funding and Investment Analysis: Cumulative Number of Instances by Year, 2014-2019
Figure 9.3. Funding and Investment Analysis: Distribution by Type of Funding and Year,
Figure 9.4. Funding and Investment Analysis: Cumulative Amount Invested, 2014-2019 (USD Million)
Figure 9.5. Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2014-2019
Figure 9.6. Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, 2014-2019 (USD Million)
Figure 9.7. Funding and Investment Analysis: Summary of Investments, 2014-2019 (USD Million)
Figure 9.8. Funding and Investments: Analysis by Amount Invested across Different Types of Therapies
Figure 9.9. Funding and Investment Analysis: Distribution by Amount Invested across Different Types of Indications
Figure 9.10. Funding and Investment Analysis: Distribution by Geography
Figure 9.11. Most Active Players: Distribution by Amount Invested (USD Million)
Figure 9.12. Most Active Investors: Distribution by Number of Instances
Figure 9.13. Funding and Investment Summary, 2014-2019 (USD Million)
Figure 10.1. Global Neoantigen Targeted Therapies Market, 2019-2030 (USD Million)
Figure 10.2. Global Neoantigen Targeted Therapies Market Distribution by Region, 2019-2030 (USD Million)
Figure 10.3. Global Neoantigen Targeted Therapies Market: Distribution by Target Disease Indication, 2019-2030 (USD Million)
Figure 10.4. Global Neoantigen Targeted Therapies Market for Bone and Cartilage Cancer, 2019-2030 (USD Million)
Figure 10.5. Global Neoantigen Targeted Therapies Market for Colorectal Cancer, 2019-2030 (USD Million)
Figure 10.6. Global Neoantigen Targeted Therapies Market for Gynecological Cancers, 2019-2030 (USD Million)
Figure 10.7. Global Neoantigen Targeted Therapies Market for Head and Neck Cancer, 2019-2030 (USD Million)
Figure 10.8. Global Neoantigen Targeted Therapies Market for Hepatocellular Carcinoma, 2019-2030 (USD Million)
Figure 10.9. Global Neoantigen Targeted Therapies Market for Lung Cancer, 2019-2030 (USD Million)
Figure 10.10. Global Neoantigen Targeted Therapies Market for Renal Carcinoma, 2019-2030 (USD Million)
Figure 10.11. Global Neoantigen Targeted Therapies Market for Other Cancers, 2019-2030 (USD Million)
Figure 10.12. Global Neoantigen Targeted Therapies Market: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Figure 10.13. Global Neoantigen Targeted Therapies Market for Personalized Neoantigen Therapy, 2019-2030 (USD Million)
Figure 10.14. Global Neoantigen Targeted Therapies Market for Off-the-shelf Neoantigen Therapy, 2019-2030 (USD Million)
Figure 10.15. Global Neoantigen Targeted Therapies Market: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Figure 10.16. Global Neoantigen Targeted Therapies Market for Dendritic Cell Vaccines, 2019-2030 (USD Million)
Figure 10.17. Global Neoantigen Targeted Therapies Market for DNA / RNA-based Vaccines, 2019-2030 (USD Million)
Figure 10.18. Global Neoantigen Targeted Therapies Market for Protein / Peptide-based Vaccine, 2019-2030 (USD Million)
Figure 10.19. Global Neoantigen Targeted Therapies Market for TIL-based Therapies, 2019-2030 (USD Million)
Figure 10.20. Global Neoantigen Targeted Therapies Market: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 10.21. Global Neoantigen Targeted Therapies Market for Intradermal Route of Administration, 2019-2030 (USD Million)
Figure 10.22. Global Neoantigen Targeted Therapies Market for Intravenous Route of Administration, 2019-2030 (USD Million)
Figure 10.23. Global Neoantigen Targeted Therapies Market for Subcutaneous Route of Administration, 2019-2030 (USD Million)
Figure 10.24. Global Neoantigen Targeted Therapies Market for Others Route of Administration, 2019-2030 (USD Million)
Figure 10.25. Neoantigen Targeted Therapies Market in the US, 2019-2030 (USD Million)
Figure 10.26. Neoantigen Targeted Therapies Market in the US: Distribution by Target Disease Indication, 2019-2030 (USD Million)
Figure 10.27. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Figure 10.28. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Figure 10.29. Neoantigen Targeted Therapies Market in the US: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 10.30. Neoantigen Targeted Therapies Market in the UK, 2019-2030 (USD Million)
Figure 10.31. Neoantigen Targeted Therapies Market in the UK: Distribution by Target Disease Indication, 2019-2030 (USD Million)
Figure 10.32. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Figure 10.33. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Figure 10.34. Neoantigen Targeted Therapies Market in the UK: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 10.35. Neoantigen Targeted Therapies Market in Germany, 2019-2030 (USD Million)
Figure 10.36. Neoantigen Targeted Therapies Market in Germany: Distribution by Target Disease Indication, 2019-2030 (USD Million)
Figure 10.37. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Figure 10.38. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Figure 10.39. Neoantigen Targeted Therapies Market in Germany: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 10.40. Neoantigen Targeted Therapies Market in France, 2019-2030 (USD Million)
Figure 10.41. Neoantigen Targeted Therapies Market in France: Distribution by Target Disease Indication, 2019-2030 (USD Million)
Figure 10.42. Neoantigen Targeted Therapies Market in France: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Figure 10.43. Neoantigen Targeted Therapies Market in France: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Figure 10.44. Neoantigen Targeted Therapies Market in France: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 10.45. Neoantigen Targeted Therapies Market in Italy, 2019-2030 (USD Million)
Figure 10.46. Neoantigen Targeted Therapies Market in Italy: Distribution by Target Disease Indication, 2019-2030 (USD Million)
Figure 10.47. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Figure 10.48. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Figure 10.49. Neoantigen Targeted Therapies Market in Italy: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 10.50. Neoantigen Targeted Therapies Market in Spain, 2019-2030 (USD Million)
Figure 10.51. Neoantigen Targeted Therapies Market in Spain: Distribution by Target Disease Indication, 2019-2030 (USD Million)
Figure 10.52. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Figure 10.53. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Figure 10.54. Neoantigen Targeted Therapies Market in Spain: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 10.55. Neoantigen Targeted Therapies Market in Rest of the World, 2019-2030 (USD Million)
Figure 10.56. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Target Disease Indication, 2019-2030 (USD Million)
Figure 10.57. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Figure 10.58. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Figure 10.59. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (USD Million)
List of Tables
Table 3.1. Difference between Personalized and Off-the-shelf Neoantigens
Table 3.2. List of Neoantigen Targeted Combination Therapies
Table 3.3. List of Algorithms Used for Neoantigen Prediction
Table 3.4. Delivery Strategies for Neoantigen Therapies
Table 4.1. Neoantigen Targeted Therapies: Marketed and Development Pipeline
Table 4.2. Neoantigen Targeted Therapies: List of Companies
Table 5.1. Bavarian Nordic: Company Snapshot
Table 5.2. Drug Profile: CV301
Table 5.3. Drug Profile: BN-Brachyury
Table 5.4. Bavarian Nordic: Future Outlook
Table 5.5. Genocea Biosciences: Company Snapshot
Table 5.6. Drug Profile: GEN-009
Table 5.7. Genocea Biosciences: Future Outlook
Table 5.8. Genocea Biosciences: Company Snapshot
Table 5.9. Drug Profile: Vigil®
Table 5.10. Future Outlook
Table 5.11. Immunicum: Company Snapshot
Table 5.12. Drug Profile: Ilixadencel
Table 5.13. Immunicum: Future Outlook
Table 5.14. Immunovative Therapies: Company Snapshot
Table 5.15. Drug Profile: Chaperone Rich Cell Lysate
Table 5.16. Drug Profile: AlloStim®
Table 5.17. Drug Profile: AlloVax®
Table 5.18. Immunovative Therapies: Future Outlook
Table 5.19. Iovance Biotherapeutics: Company Snapshot
Table 5.20. Drug Profile: Lifileucel (LN-144)
Table 5.21. Drug Profile: LN-145
Table 5.22. Drug Profile: MDA TIL
Table 5.23. Iovance Biotherapeutics: Future Outlook
Table 5.24. MediGene: Company Snapshot
Table 5.25. Drug Profile: WT1 / PRAME
Table 5.26. Drug Profile: MDG1011
Table 5.27. MediGene: Future Outlook
Table 5.28. Neon Therapeutics: Company Snapshot
Table 5.29. Drug Profile: NEO-PV-01
Table 5.30. Drug Profile: NEO-PTC-01
Table 5.31. Drug Profile: NEO-SV-01
Table 5.32. Neon Therapeutics: Future Outlook
Table 6.1. Neoantigen Targeted Therapies: List of Publications, 2017-2018
Table 7.1. Patent Analysis: CPC Classification Symbol Definitions
Table 7.2. Patent Analysis: Popular CPC Classification Symbols
Table 7.3. Patent Analysis: List of Top CPC Classifications
Table 7.4. Patent Analysis: List of Leading Individual Assignees
Table 7.5. Patent Analysis: Benchmarking Analysis Summary
Table 7.6. Patent Analysis: List of Leading Patents (by Highest Relative Valuation)
Table 8.1. Neoantigen Targeted Therapies: Partnerships and Collaborations, 2014-2019
Table 9.1. Neoantigen Targeted Therapies: Funding and Investments, 2014-2019
Table 13.1. Neoantigen Targeted Therapies: Distribution by Phase of Development
Table 13.2. Neoantigen Targeted Therapies: Distribution by Type of Molecule
Table 13.3. Neoantigen Targeted Therapies: Distribution by Type of Immunotherapy
Table 13.4. Neoantigen Targeted Therapies: Distribution by Type of Therapy
Table 13.5. Neoantigen Targeted Therapies: Distribution by Route of Administration
Table 13.6. Neoantigen Targeted Therapies: Distribution by Target Disease Indication
Table 13.7. Neoantigen Targeted Therapies: Distribution by Type of Neoantigen
Table 13.8. Neoantigen Targeted Therapies: Distribution by Line of Therapy
Table 13.9. Neoantigen Targeted Therapies: Distribution by Year of Establishment of Developer
Table 13.10. Neoantigen Targeted Therapies: Distribution by Company Size and Geographical Location
Table 13.11. Leading Developers: Distribution by Number of Therapies
Table 13.12. Neoantigen Targeted Therapies: Distribution by Geographical Location
Table 13.13. Bavarian Nordic: Annual Revenues, FY2014-FY2018 (DKK Million)
Table 13.14. MediGene: Annual Revenues, FY2014-FY2018 (EUR Million)
Table 13.15. Publications: Year of Publication
Table 13.16. Publications: Distribution by Type of Study
Table 13.17. Publications: Distribution by Study Objective
Table 13.18. Publications: Distribution by Affiliated Therapies
Table 13.19. Publications: Distribution by Target Disease Indication
Table 13.20. Key Journals: Distribution by Number of Publications
Table 13.21. Patent Analysis: Distribution by Type of Patent
Table 13.22. Patent Analysis: Cumulative Distribution by Publication Year, Pre2010-2019
Table 13.23. Patent Analysis: Distribution by Geographical Location
Table 13.24. Patent Analysis: Distribution by Geographical Location, 2000-200 9 and 2010-2019
Table 13.25. Patent Analysis: Distribution by Type of Applicant
Table 13.26. Leading Industry Players: Distribution by Number of Patents
Table 13.27. Leading Non-Industry Players: Distribution by Number of Patents
Table 13.28. Patent Analysis: Leading Individual Assignees
Table 13.29. Patent Analysis: Distribution by Patent Age (January 2000 - April 2019)
Table 13.30. Patent Analysis: Valuation Analysis
Table 13.31. Partnerships and Collaborations: Cumulative Trend by Year, 2014-2019
Table 13.32. Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.33. Partnerships and Collaborations: Distribution by Type of Partnership, 2014-2016 and 2017-2019
Table 13.34. Partnerships and Collaborations: Distribution by Type of Product
Table 13.35. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Immunotherapy
Table 13.36. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Target Disease Indication
Table 13.37. Most Active Players: Distribution by Number of Partnerships
Table 13.38. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 13.39. Funding and Investments: Distribution by Type of Funding and Year of Establishment, 2014-2019
Table 13.40. Funding and Investments: Cumulative Number of Instances by Year, 2014-2019
Table 13.41. Funding and Investments: Distribution by Type of Funding and Year, 2014-2019
Table 13.42. Funding and Investments: Cumulative Amount Invested, 2014-2019 (USD Million)
Table 13.43. Funding and Investments: Distribution of Instances by Type of Funding, 2014-2019
Table 13.44. Funding and Investments: Distribution of the Total Amount Invested by Type of Funding, 2014-2019 (USD Million)
Table 13.45. Funding and Investments: Summary of Investments, 2014-2019 (USD Million)
Table 13.46. Funding and Investments: Analysis by Amount Invested across Different Types of Therapies
Table 13.47. Funding and Investments: Distribution by Amount Invested across Different Types of Indications
Table 13.48. Funding and Investments: Distribution by Geography
Table 13.49. Most Active Players: Distribution by Amount Invested (USD Million)
Table 13.50. Most Active Investors: Distribution by Number of Instances
Table 13.51. Funding and Investments Summary, 2014-2019 (USD Million)
Table 13.52. Global Neoantigen Targeted Therapies Market, 2019-2030 Base, Optimistic, Conservative Case (USD Billion)
Table 13.53. Global Neoantigen Targeted Therapies Market Distribution by Region, 2019-2030 (USD Million)
Table 13.54. Global Neoantigen Targeted Therapies Market: Distribution by Target Disease Indication, 2019-2030 (USD Million)
Table 13.55. Global Neoantigen Targeted Therapies Market for Bone and Cartilage Cancer, 2019-2030 (USD Million)
Table 13.56. Global Neoantigen Targeted Therapies Market for Colorectal Cancer, 2019-2030 (USD Million)
Table 13.57. Global Neoantigen Targeted Therapies Market for Gynecological Cancers, 2019-2030 (USD Million)
Table 13.58. Global Neoantigen Targeted Therapies Market for Head and Neck Cancer, 2019-2030 (USD Million)
Table 13.59. Global Neoantigen Targeted Therapies Market for Hepatocellular Carcinoma, 2019-2030 (USD Million)
Table 13.60. Global Neoantigen Targeted Therapies Market for Lung Cancer, 2019-2030 (USD Million)
Table 13.61. Global Neoantigen Targeted Therapies Market for Renal Carcinoma, 2019-2030
Table 13.62. Global Neoantigen Targeted Therapies Market for Other Cancers, 2019-2030 (USD Million)
Table 13.63. Global Neoantigen Targeted Therapies Market: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Table 13.64. Global Neoantigen Targeted Therapies Market for Personalized Neoantigen Therapy, 2019-2030 (USD Million)
Table 13.65. Global Neoantigen Targeted Therapies Market for Off-the-shelf Neoantigen Therapy, 2019-2030 (USD Million)
Table 13.66. Global Neoantigen Targeted Therapies Market: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Table 13.67. Global Neoantigen Targeted Therapies Market for Dendritic Cell Vaccines, 2019-2030 (USD Million)
Table 13.68. Global Neoantigen Targeted Therapies Market for DNA / RNA-based Vaccines, 2019-2030 (USD Million)
Table 13.69. Global Neoantigen Targeted Therapies Market for Protein / Peptide-based Vaccine, 2019-2030 (USD Million)
Table 13.70. Global Neoantigen Targeted Therapies Market for TIL-based Therapies, 2019-2030 (USD Million)
Table 13.71. Global Neoantigen Targeted Therapies Market: Distribution by Route of Administration, 2019-2030 (USD Million)
Table 13.72. Global Neoantigen Targeted Therapies Market for Intradermal Route of Administration, 2019-2030 (USD Million)
Table 13.73. Global Neoantigen Targeted Therapies Market for Intravenous Route of Administration, 2019-2030 (USD Million)
Table 13.74. Global Neoantigen Targeted Therapies Market for Subcutaneous Route of Administration, 2019-2030 (USD Million)
Table 13.75. Global Neoantigen Targeted Therapies Market for Others Route of Administration, 2019-2030 (USD Million)
Table 13.76. Neoantigen Targeted Therapies Market in the US, 2019-2030, Base, Optimistic, Conservative Case (USD Million)
Table 13.77. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Target Disease Indication, 2019-2030 (USD Million)
Table 13.78. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Table 13.79. Neoantigen Targeted Therapies Market in the US: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Table 13.80. Neoantigen Targeted Therapies Market in the US: Distribution by Route of Administration, 2019-2030 (USD Million)
Table 13.81. Neoantigen Targeted Therapies Market in the UK, 2019-2030, Base, Optimistic, Conservative Case (USD Million)
Table 13.82. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Target Disease Indication, 2019-2030 (USD Million)
Table 13.83. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Table 13.84. Neoantigen Targeted Therapies Market in the UK: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Table 13.85. Neoantigen Targeted Therapies Market in the UK: Distribution by Route of Administration, 2019-2030 (USD Million)
Table 13.86. Neoantigen Targeted Therapies Market in Germany, 2019-2030, Base, Optimistic, Conservative Case (USD Million)
Table 13.87. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Target Disease Indication, 2019-2030 (USD Million)
Table 13.88. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Table 13.89. Neoantigen Targeted Therapies Market in Germany: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Table 13.90. Neoantigen Targeted Therapies Market in Germany: Distribution by Route of Administration, 2019-2030 (USD Million)
Table 13.91. Neoantigen Targeted Therapies Market in France, 2019-2030, Base, Optimistic, Conservative Case (USD Million)
Table 13.92. Neoantigen Targeted Therapies Market in France: Distribution by Type of Target Disease Indication, 2019-2030 (USD Million)
Table 13.93. Neoantigen Targeted Therapies Market in France: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Table 13.94. Neoantigen Targeted Therapies Market in France: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Table 13.95. Neoantigen Targeted Therapies Market in France: Distribution by Route of Administration, 2019-2030 (USD Million)
Table 13.96. Neoantigen Targeted Therapies Market in Italy, 2019-2030, Base, Optimistic, Conservative Case (USD Million)
Table 13.97. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Target Disease Indication, 2019-2030 (USD Million)
Table 13.98. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Table 13.99. Neoantigen Targeted Therapies Market in Italy: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Table 13.100. Neoantigen Targeted Therapies Market in Italy: Distribution by Route of Administration, 2019-2030 (USD Million)
Table 13.101. Neoantigen Targeted Therapies Market in Spain, 2019-2030, Base, Optimistic, Conservative Case (USD Million)
Table 13.102. Neoantigen Targeted Therapies Market in Spain: Distribution by Target Disease Indication, 2019-2030 (USD Million)
Table 13.103. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Table 13.104. Neoantigen Targeted Therapies Market in Spain: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Table 13.105. Neoantigen Targeted Therapies Market in Spain: Distribution by Route of Administration, 2019-2030 (USD Million)
Table 13.106. Neoantigen Targeted Therapies Market in Rest of the World, Base, Optimistic, Conservative Case, 2019-2030 (USD Million)
Table 13.107. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Target Disease Indication, 2019-2030 (USD Million)
Table 13.108. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Neoantigen, 2019-2030 (USD Million)
Table 13.109. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Type of Immunotherapy, 2019-2030 (USD Million)
Table 13.110. Neoantigen Targeted Therapies Market in Rest of the World: Distribution by Route of Administration, 2019-2030 (USD Million)